ORMP

Q: What is the price of Oramed Pharmaceuticals (ORMP) today?

The current price of Oramed Pharmaceuticals (ORMP) is $ 3.88, representing a 93.13% gain over the past year. The stock began the year trading around $ 2.85 and is currently priced at $ 3.88. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Oramed Pharmaceuticals (ORMP) pay dividends?

In the last year, Oramed Pharmaceuticals (ORMP) distributed dividends in the month of January, totaling $ 0.25. The Dividend Yield for the last 12 months is 6.44%.

Oramed Pharmaceuticals Inc.

Price

$ 3.88

return (12m)

93.13%

p/e

2.48

p/bv

0.80

DIVIDEND YIELD

6.44%

ORMP price

ORMP

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment ORMP

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

11.17%

3 months

13.10%

1 year

93.13%

2 years

83.35%

5 years

-54.86%

10 years

-52.00%

Fundamentals ORMP

review the fundamentals of Oramed Pharmaceuticals shares

P/E

2.48

Sector: -4.11 Industry: -4.11

P/S (PSR)

79.54

Sector: -3.78 Industry: -3.78

P/BV

0.80

Sector: 1.95 Industry: 1.95

DIVIDEND YIELD (DY)

6.44%

Sector: - Industry: -

ROA

27.75%

Sector: -61.23% Industry: -61.23%

ROE

32.07%

Sector: -60.44% Industry: -60.44%

ROIC

-24.55%

Sector: -1,165.26% Industry: -1,165.26%

NET MARGIN

100.00%

Sector: -39.16% Industry: -39.16%

GROSS MARGIN

0.50%

Sector: 37.92% Industry: 37.92%

OPERATING MARGIN

-100.00%

Sector: -39.32% Industry: -39.32%

EV/EBITDA

2.04

Sector: -4.00 Industry: -4.00

EV/EBIT

2.04

Sector: -4.22 Industry: -4.22

PRICE-TO-ASSETS

0.69

Sector: 1.44 Industry: 1.44

BVPS

4.87

Sector: 1.88 Industry: 1.88

EPS

1.56

Sector: -2.05 Industry: -2.05

EQUITY-TO-ASSETS RATIO

0.87

Sector: 0.42 Industry: 0.42

LIABILITIES / ASSETS

0.13

Sector: 0.38 Industry: 0.38

CAGR REVENUE 5 YEARS

-5.76%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF Oramed Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 3.88

Fair Value

$ 0.00

Upside/Downside Return potential.

236.97%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ORMP

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	20.93	7.08	33.81%	2.23%	$ 560.91 B	28.46%
PFE	20.17	1.68	8.35%	6.24%	$ 156.71 B	12.42%
ABBV	87.13	0.00	0.00%	3.19%	$ 368.21 B	6.91%
NVO	11.49	5.92	51.50%	4.60%	$ 179.95 B	33.05%
MRK	16.19	0.00	0.00%	2.79%	$ 295.53 B	28.08%
AZN	31.07	6.52	20.99%	1.56%	$ 317.64 B	17.41%
GILD	20.09	7.56	37.62%	2.32%	$ 170.95 B	28.90%
BMY	17.19	-3.56	-20.72%	4.18%	$ 121.26 B	14.64%
ZTS	20.05	16.09	80.25%	1.66%	$ 53.60 B	28.23%
REGN	17.16	2.47	14.41%	0.48%	$ 77.31 B	31.41%
HALO	25.80	167.51	649.21%	0.00%	$ 8.18 B	22.69%
AMGN	24.84	22.12	89.06%	2.72%	$ 191.51 B	20.98%
MCK	24.55	-1,076.41	-4,383.84%	0.37%	$ 106.56 B	1.09%
VRTX	28.35	6.00	21.18%	0.00%	$ 112.06 B	32.94%
CAH	30.39	-18.70	-61.56%	0.95%	$ 50.50 B	0.68%
HRMY	10.77	1.96	18.24%	0.00%	$ 1.71 B	18.27%
ADMA	17.83	5.49	30.78%	0.00%	$ 2.62 B	28.80%
BIIB	20.16	1.43	7.08%	0.00%	$ 26.07 B	13.07%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

ORMP Historical Dividends

current DY: 6.44%

5-year average DY: 0.00%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	01/16/2026	01/26/2026	0,25000000

ABOUT Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (1 people)

United States

24 years

Founded: 2002

2007

Time since IPO - 19 years

12

Employees

Oramed Pharmaceuticals Inc. (United States) is listed on the Nasdaq and has a market capitalization of $159.08 Millions, with shareholders equity totaling $199.74 Millions.

The company employs approximately 12 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Oramed Pharmaceuticals Inc. reported $2.00 Millions in revenue, generating net income of $64.06 Millions.

Key financial metrics include a P/E ratio of 2.48, a price-to-book (P/B) ratio of 0.80, and a trailing twelve-month dividend yield of 6.44%.

The company trades under the ticker ORMP.

Market cap

$ 159.08 Millions

Net worth

$ 199.74 Millions

$ 199,740,000.00

Assets

$ 230.86 Millions

$ 230,860,000.00

Total Shares Outstanding

41.00 Millions

41,000,000

Average Daily Trading Volume

$ 134.72 Thousand

$ 134,724.00

Sector

Health Care

Industry

Biotechnology

ORMP

ORMP revenue and profits

Financial Results ORMP

DRAG THE FRAME TO SEE MORE DATA

ORMP cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 866.38 24,78% (12M)

P/E

24.55

0.37%

ROE

-4,383.84%

P/BV

-1,076.41

CAH - Cardinal Health

$ 213.99 60,64% (12M)

P/E

30.39

0.95%

ROE

-61.56%

P/BV

-18.70

JNJ - Johnson & Johnson

$ 234.18 53,74% (12M)

P/E

20.93

2.23%

ROE

33.81%

P/BV

7.08

PFE - Pfizer

$ 27.56 33,52% (12M)

P/E

20.17

6.24%

ROE

8.35%

P/BV

1.68

ABBV - AbbVie

$ 208.38 25,43% (12M)

P/E

87.13

3.19%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 119.07 58,20% (12M)

P/E

16.19

2.79%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$ 204.80 55,80% (12M)

P/E

31.07

1.56%

ROE

20.99%

P/BV

6.52

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 866.38 24,78% (12 M)

P/L

24.55

0.37%

ROE

-4,383.84%

P/VP

-1,076.41

CAH - Cardinal Health

$ 213.99 60,64% (12 M)

P/L

30.39

0.95%

ROE

-61.56%

P/VP

-18.70

JNJ - Johnson & Johnson

$ 234.18 53,74% (12 M)

P/L

20.93

2.23%

ROE

33.81%

P/VP

7.08

PFE - Pfizer

$ 27.56 33,52% (12 M)

P/L

20.17

6.24%

ROE

8.35%

P/VP

1.68

ABBV - AbbVie

$ 208.38 25,43% (12 M)

P/L

87.13

3.19%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 119.07 58,20% (12 M)

P/L

16.19

2.79%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 204.80 55,80% (12 M)

P/L

31.07

1.56%

ROE

20.99%

P/VP

6.52

Frequently Asked Questions

What is the price of Oramed Pharmaceuticals (ORMP) today?

The current price of Oramed Pharmaceuticals (ORMP) is $ 3.88, representing a 93.13% gain over the past year. The stock began the year trading around $ 2.85 and is currently priced at $ 3.88. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Oramed Pharmaceuticals (ORMP) pay dividends?

In the last year, Oramed Pharmaceuticals (ORMP) distributed dividends in the month of January, totaling $ 0.25. The Dividend Yield for the last 12 months is 6.44%.

Is Oramed Pharmaceuticals (ORMP) a good investment?

Oramed Pharmaceuticals (ORMP) is currently trading at $ 3.88 with a P/E ratio of 2.48%. This represents a 46% premium compared to its historical average P/E. Over the past year, the stock has gained 93.13 and paid $ 0.25 in dividends, resulting in a dividend yield of 6.44%. The total shareholder return over the same period was 93.13%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Oramed Pharmaceuticals (ORMP) stock?

You can buy Oramed Pharmaceuticals (ORMP) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol ORMP and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Oramed Pharmaceuticals (ORMP) yield today?

Over the past month, Oramed Pharmaceuticals (ORMP) has returned 11.17% — 93.13% over the past year, and -54.86% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.25 per share in dividends, resulting in a dividend yield of 6.44%.

If you were to purchase 100 shares of Oramed Pharmaceuticals (ORMP) today at the current price of $ 3.88 your total investment would be $ 388.00.

Based on historical performance, the investment would have grown to approximately:

$ 749.34 after 1 year
$ 175.14 after 5 years
$ 186.24 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

ORMP

Oramed Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment ORMP

review the fundamentals of Oramed Pharmaceuticals shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 6.44%

5-year average DY: 0.00%

type

Ex - Dividend Date

payment date

value

ABOUT Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc.

United States

24 years

2007

12

PROFIT X PRICE ORMP

Financial Results ORMP

ORMP cash flow

Asset, Revenue and Profit Growth - ORMP

ORMP balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions